Samjot Singh Dhillon1, Todd L Demmy2, Sai Yendamuri3, Gregory Loewen4, Chukwumere Nwogu3, Michele Cooper5, Barbara W Henderson5. 1. Department of Medicine-Pulmonary Medicine/Thoracic Oncology, Roswell Park Cancer Institute, Buffalo, NY. Electronic address: samjot.dhillon@roswellpark.org. 2. Sections of Thoracic Oncology and Thoracic Surgery, Department of Surgery, Robert Wood Johnson Medical School, New Brunswick, NJ. 3. Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, NY. 4. Washington State University, Spokane, WA. 5. Department of Photodynamic Therapy, Roswell Park Cancer Institute, Buffalo, NY.
Abstract
INTRODUCTION: We report a phase I trial of photodynamic therapy (PDT) of carcinoma in situ (CIS) and microinvasive cancer (MIC) of the central airways with the photosensitizer (PS) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH). HPPH has the advantage of minimal general phototoxicity over the commonly used photosensitizer porfimer sodium (Photofrin; Pinnacle Biologics, Chicago, IL). METHODS: The objectives of this study were (1) to determine the maximally tolerated light dose at a fixed photosensitizer dose and (2) to gain initial insight into the effectiveness of this treatment approach. Seventeen patients with 21 CIS/MIC lesions were treated with HPPH with light dose escalation starting from 75 J/cm2 and increasing to 85, 95,125, and 150 J/cm2 respectively. Follow-up bronchoscopy for response assessment was performed at 1 and 6 months, respectively. RESULTS: The rate of pathological complete response (CR) was 82.4% (14 of 17 evaluable lesions; 14 patients) at 1 month and 72.7% (8/11 evaluable lesions; 8 patients) at 6 months. Only four patients developed mild skin erythema. One of the three patients in the 150 J/cm2 light dose group experienced a serious adverse event. This patient had respiratory distress caused by mucus plugging, which precipitated cardiac ischemia. Two additional patients treated subsequently at this light dose had no adverse events. The sixth patient in this dose group was not recruited and the study was terminated because of delays in HPPH supply. However, given the observed serious adverse event, it is recommended that the light dose does not exceed 125 J/cm2. CONCLUSIONS: PDT with HPPH can be safely used for the treatment of CIS/MIC of the airways, with potential effectiveness comparable to that reported for porfimer sodium in earlier studies.
INTRODUCTION: We report a phase I trial of photodynamic therapy (PDT) of carcinoma in situ (CIS) and microinvasive cancer (MIC) of the central airways with the photosensitizer (PS) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH). HPPH has the advantage of minimal general phototoxicity over the commonly used photosensitizer porfimer sodium (Photofrin; Pinnacle Biologics, Chicago, IL). METHODS: The objectives of this study were (1) to determine the maximally tolerated light dose at a fixed photosensitizer dose and (2) to gain initial insight into the effectiveness of this treatment approach. Seventeen patients with 21 CIS/MIC lesions were treated with HPPH with light dose escalation starting from 75 J/cm2 and increasing to 85, 95,125, and 150 J/cm2 respectively. Follow-up bronchoscopy for response assessment was performed at 1 and 6 months, respectively. RESULTS: The rate of pathological complete response (CR) was 82.4% (14 of 17 evaluable lesions; 14 patients) at 1 month and 72.7% (8/11 evaluable lesions; 8 patients) at 6 months. Only four patients developed mild skin erythema. One of the three patients in the 150 J/cm2 light dose group experienced a serious adverse event. This patient had respiratory distress caused by mucus plugging, which precipitated cardiac ischemia. Two additional patients treated subsequently at this light dose had no adverse events. The sixth patient in this dose group was not recruited and the study was terminated because of delays in HPPH supply. However, given the observed serious adverse event, it is recommended that the light dose does not exceed 125 J/cm2. CONCLUSIONS: PDT with HPPH can be safely used for the treatment of CIS/MIC of the airways, with potential effectiveness comparable to that reported for porfimer sodium in earlier studies.
Authors: Hector R Nava; Shyam S Allamaneni; Thomas J Dougherty; Michele T Cooper; Wei Tan; Gregory Wilding; Barbara W Henderson Journal: Lasers Surg Med Date: 2011-09 Impact factor: 4.025
Authors: Charles B Simone; Joseph S Friedberg; Eli Glatstein; James P Stevenson; Daniel H Sterman; Stephen M Hahn; Keith A Cengel Journal: J Thorac Dis Date: 2012-02 Impact factor: 2.895
Authors: K Furuse; M Fukuoka; H Kato; T Horai; K Kubota; N Kodama; Y Kusunoki; N Takifuji; T Okunaka; C Konaka Journal: J Clin Oncol Date: 1993-10 Impact factor: 44.544
Authors: Nestor Rigual; Gal Shafirstein; Michele T Cooper; Heinz Baumann; David A Bellnier; Ulas Sunar; Erin C Tracy; Daniel J Rohrbach; Gregory Wilding; Wei Tan; Maureen Sullivan; Mihai Merzianu; Barbara W Henderson Journal: Clin Cancer Res Date: 2013-10-02 Impact factor: 12.531
Authors: Collin T Inglut; Kelsey M Gray; Shruti Vig; Jae W Jung; Jillian Stabile; Yuji Zhang; Kimberly M Stroka; Huang-Chiao Huang Journal: IEEE J Sel Top Quantum Electron Date: 2020-09-15 Impact factor: 4.653
Authors: Lucien N Lameijer; Daniël Ernst; Samantha L Hopkins; Michael S Meijer; Sven H C Askes; Sylvia E Le Dévédec; Sylvestre Bonnet Journal: Angew Chem Int Ed Engl Date: 2017-08-09 Impact factor: 15.336